Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL492457 | 0.98 | KDM4E (0.42) | KDM4EGAALMNACCR1CCR5 | |
| Hydrochloric Acid SCHEMBL492359 | 0.98 | KDM4E (0.42) | KDM4EGAALMNACCR1CCR5 | |
| Hydrochloric Acid SCHEMBL492462 | 0.98 | KDM4E (0.42) | KDM4EGAALMNACCR1CCR5 | |
| Bromide SCHEMBL492578 | 0.96 | KDM4E (0.41) | KDM4EGAALMNACCR1CCR5 | |
| SCHEMBL492442 | 0.96 | KDM4E (0.44) | KDM4EGAALMNACCR1CCR5 | |
| Hydrochloric Acid SCHEMBL492668 | 0.94 | KDM4E (0.42) | KDM4EGAALMNACCR1CCR5 | |
| SCHEMBL4575603 | 0.94 | KDM4E (0.42) | KDM4EGAALMNACCR1CCR5 | |
| SCHEMBL18406133 | 0.89 | KDM4E (0.41) | KDM4EGAALMNACCR1CCR5 | |
| SCHEMBL18412682 | 0.89 | KDM4E (0.41) | KDM4EGAALMNACCR1CCR5 | |
| SCHEMBL9335973 | 0.84 | CYP1A2 (0.41) | KDM4EGAALMNACCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876182-B1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | NIPPON CHEMICAL IND (JP) | 2012-12-19 | — | — | EP | claimed |
| US-8106186-B2 | Transition metal phosphine complex, method for producing same, and anticancer agent containing transition metal phospine complex | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2012-01-31 | — | — | US | claimed |
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2009-03-19 | — | — | US | claimed |
| EP-1876182-A1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | Nippon Chemical Industrial Co., Ltd. (JP) | 2008-01-09 | — | — | EP | claimed |
| EP-1876182-B1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | NIPPON CHEMICAL IND (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8106186-B2 | Transition metal phosphine complex, method for producing same, and anticancer agent containing transition metal phospine complex | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1876182-A1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | Nippon Chemical Industrial Co., Ltd. (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | CDKL1, MASTL, AARS1 | KDM4E 3657/4885GAA 2569/4885LMNA 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.